Table 1 Baseline demographic data of the patients.
Crohn’s disease (n = 39) | Ulcerative colitis (n = 28) | |
|---|---|---|
Age at VDZ initiation, median (IQR), years | 35.0 (29.0–43.0) | 47.5 (35.8–50.3) |
Disease duration, median (IQR), years | 13.6 (9.5–17.2) | 3.6 (2.6–6.7) |
Male, n (%) | 26 (66.7) | 16 (57.1) |
BMI, median (IQR), kg/m2 | 19.6 (17.2–23.0) | 21.1 (19.5–24.2) |
Family history of IBD, n (%) | 0 (0.0) | 2 (7.1) |
Smoking history, n (%) | ||
Never smoker | 33 (84.6) | 20 (71.4) |
Ex-smoker | 4 (10.3) | 7 (25.0) |
Current smoker | 2 (5.1) | 1 (3.6) |
Patients with an ostomy, n (%) | 5 (12.8) | 0 (0.0) |
IBD phenotypea, n (%) | ||
Disease location | ||
Ileal (L1) | 5 (12.8) | |
Colonic (L2) | 1 (2.6) | |
Ileocolonic (L3) | 33 (84.6) | |
Disease behavior | ||
Non-stricturing/non-penetrating (B1) | 5 (12.8) | |
Stricturing (B2) | 10 (25.6) | |
Penetrating (B3) | 24 (61.5) | |
Perianal disease modifier | 21 (53.8) | |
Disease extent | ||
Left-sided colitis (E2) | 8 (28.6) | |
Extensive colitis (E3) | 20 (71.4) | |
Previous exposure to TNF inhibitors, n (%) | 39 (100.0) | 28 (100.0) |
Concomitant CS, n (%) | 3 (7.7) | 13 (46.4) |
Concomitant IMMs, n (%) | 24 (61.5) | 11 (39.3) |
Disease activity at VDZ initiation | ||
Crohn’s disease activity index, median (IQR) | 173.5 (124.5–217.8) | |
Partial Mayo score, median (IQR) | 6.0 (5.0–7.0) | |
Baseline albumin, median (IQR) (g/dL) | 3.3 (3.1–3.8) | 3.6 (3.2–3.9) |
Baseline C-reactive protein, median (IQR) (mg/dL) | 1.2 (0.6–2.4) | 0.8 (0.1–1.2) |
Baseline fecal calprotectinb, median (IQR) (mg/kg) | 694.0 (525.0–1230.0) | 1543.5 (689.8–4657.5) |
